The global Crohn’s disease drug market is forecast to reach USD 13.72 Billion by 2027, according to a new report by Reports and Data.
The global Crohn’s disease drug market is forecast to reach USD 13.72 Billion by 2027, according to a new report by Reports and Data. Crohn’s disease is a chronic condition, which can be defined as an inflammatory bowel disease (IBD). It is also known as regional enteritis or ileitis. The condition results in bowel, intestine, or other areas of the digestive tract to become ulcerated and inflamed. It usually affects the ileum and the beginning of the colon. There is no one specific test for diagnosing the disease. Doctors often combine various tests to confirm the diagnosis of the condition like tests for infection or anemia and fecal occult blood test. There is no cure for the Chrohn’s disease at present, and no one standardized treatment works for all the care users.
Access Free sample PDF Copy of the Report (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.reportsanddata.com/sample-enquiry-form/2381
The goal of the prescribed medications for the condition is minimizing inflammation that triggers the symptoms and signs of the disease. The medicines are also prescribed, aiming at reducing symptoms of diarrhea, pain, bleeding, and eliminate nutritional deficiencies. Treatment of the illness may also involve nutritional supplements, surgery, drugs, or a combination of these therapies. There are various types of medications prescribed for treating the condition. A large number of care users are usually treated with sulfasalazine (Azulfidine). Another frequently prescribed medication is 5-aminosalicylic acid or 5-ASA medication. These medications are effective in reducing inflammation.
Further key findings from the report suggest
-
- The Crohn’s Disease Drug market held a market share of USD 9.96 Billion in the year 2018 that is forecasted to grow at a rate of 3.6% during the forecast period.
- In context to Drug Type, the Anti-Interleukin Biologics segment is projected to witness the fastest growth rate of 25.0% during the forecast period, which is expected to occupy 8.0% of the market by 2027. Advancements in this type of drug, associated with new launches and its effectiveness in reducing inflammation associated with the condition is resulting in its growing demand, also contributes to the growth rate of this segment.
- In context to Route of Administration, the Oral segment is projected to witness a faster growth rate of 4.3% during the forecast period, which is expected to occupy 45.0% of the market by 2027. The growth rate witnessed by the segment is attributed to the presence of strong pipeline products and continuous development in various drugs like JAK inhibitors. The ease of its consumption over injectable has a positive impact on the growth rate of this segment.
- In context to Distribution Channel, the Hospitals Pharmacy segment held the largest market share of 40.0% in 2018, with a CAGR of 3.4% during the forecast period. The market share occupied by the Hospitals Pharmacy segment is resultant of rising incidence rate of the condition, increase in the number of in-patient and out-patients, elevation in the number of hospitalization associated with the disease, which results in high demand for medications of the disease from this distribution channel.
- In regards to the region, Asia Pacific is projected to witness the fastest growth rate of 4.1% during the forecast, which is expected to hold 0% of the market by 2027. The growth rate witnessed by the region is resultant of changing lifestyle that triggers the number of patients affected by this condition along with expansion of the health care sector, which is supporting the market growth in this region.
The ongoing pandemic is significantly changing the dynamics of the pharma and healthcare sector. Various countries are facing challenges such as shortage of medicines, vaccines, healthcare devices in hospitals. This is expected to open lucrative growth opportunities for market players in the coming years.
For Inquiry Before Buying @ https://www.reportsanddata.com/inquiry-before-buying/2381
Competitive Landscape:
The global market comprises various market players operating at regional and global levels. These key players are adopting various strategies such as R&D investments, license agreements, partnerships, merger and acquisitions, collaborations, and joint ventures to gain robust footing in the market.
Top Companies Profiled in the Report:
Johnson & Johnson, AbbVie Inc., Galapagos, Celgene, Gilead, Genentech, RedHill Biopharma, Mesoblast, Takeda, and Shire.
Browse Full Report Description with Research Methodology, Table of Content and Infographics @ https://www.reportsanddata.com/report-detail/crohns-disease-drug-market
Crohn’s Disease Drug Market Segmentation:
Drug Type Outlook (Revenue, USD Billion; 2016-2027)
- Aminosalicylates
- Anti-TNF Biologics
- Anti-Integrin Biologics
- MAdCAM-1Inhibitor
- Immunomodulators
- Anti-Interleukin Biologics
- Biosimilars
- JAK Inhibitors
- Smad7 Inhibitors
- Steroids
Route of Administration Outlook (Revenue, USD Billion; 2016-2027)
-
- Oral
- Injectable
Regional Outlook:
- North America (U.S., Canada, Mexico)
- Europe (Germany, U.K., Italy, France, BENELUX, Rest of Europe)
- Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
- Latin America (Brazil, Rest of LATAM)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Ask for Customize Research Report @ https://www.reportsanddata.com/request-customization-form/2381
This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges, that will determine the market’s future growth.
Press Release Available @ https://www.reportsanddata.com/press-release/global-crohns-disease-drug-market
Explore More Industry Research by Reports and Data:
Protein Engineering Market Analysis, By Product (Instruments, Consumables, Software and Services), By Type (Monoclonal Antibodies, Erythropoietin, Interferons, Others), By Technology, By End Use And By Region Forecasts To 2027 Download PDF Brochure
Immune Thrombocytopenia (ITP) Market By Products (Intravenous Immunoglobulin (IVIG), Spleen Tyrosine Kinase Inhibitor, Anti-D Immunoglobulin, Rho (D) immunoglobulin intravenous), by type (Acute And Chronic), And By End Use Forecasts To 2027 Download PDF Brochure
Smoke Evacuation Systems Market By Product (Smoke Evacuation Pencils and Wands, Smoke Evacuating Filters, Smoke-Evac Fusion Products (Shrouds)), By Application (Laparoscopic, Medical Aesthetic), By End-Use Verticals (Hospital and Clinics, Ambulatory Surgical Centers (ASCs)), Forecasts To 2027 Download PDF Brochure
Automated Insulin Delivery Systems Market Analysis, By Type (Devices, Software and Mobile App), By Applications (Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus), By End Use (Hospitals, Clinics) Forecasts To 2027 Download PDF Brochure
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs
Read the innovative blog at https://www.reportsanddata.com/blogs
Check out our upcoming research report at https://www.reportsanddata.com/upcoming-reports
For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update: https://www.youtube.com/channel/UChLqKTFLm6sVBLEUjnadIhQ/videos